Dr. Yong-Hwan Kim obtained his PhD in neuroscience from UCLA in February 2006, studying sexual dimorphism in brains. Prior to his doctoral education, he completed his BS and MS degrees at Korea University, Seoul, South Korea. He started his first post-doctoral training at Johns Hopkins University School of Medicine under the supervision of Dr. Mike Lee and Dr. Don Price and then joined Dr. Julie Andersen’s lab at the Buck Institute for Aging Research as a senior post-doc. In 2012, he established his own lab as a tenure-track assistant professor at Delaware State University (DSU), and since 2017, he has been a tenured associate professor.
As a PI at DSU, he has focused on studying the role of post-translational modifications such as SUMOylation in the pathology of Parkinson’s disease (PD) and developing potential therapeutics for PD. Recently, his lab established new projects based on their findings that cellular senescence markers, such as LaminB1 and HMGB1, stimulate the cell cycle-arrester p21 in PD pathology. His career goal as a researcher is to develop potential therapeutics for preventing or slowing Parkinson’s disease progression as well as alleviating its symptoms based on understanding the pathology of PD. Since 2002, he has been a member of the Society for Neuroscience (SfN).
Dr. Yong-Hwan Kim obtained his PhD in neuroscience from UCLA in February 2006, studying sexual dimorphism in brains. Prior to his doctoral education, he completed his BS and MS degrees at Korea University, Seoul, South Korea. He started his first post-doctoral training at Johns Hopkins University School of Medicine under the supervision of Dr. Mike Lee and Dr. Don Price and then joined Dr. Julie Andersen’s lab at the Buck Institute for Aging Research as a senior post-doc. In 2012, he established his own lab as a tenure-track assistant professor at Delaware State University (DSU), and since 2017, he has been a tenured associate professor.
As a PI at DSU, he has focused on studying the role of post-translational modifications such as SUMOylation in the pathology of Parkinson’s disease (PD) and developing potential therapeutics for PD. Recently, his lab established new projects based on their findings that cellular senescence markers, such as LaminB1 and HMGB1, stimulate the cell cycle-arrester p21 in PD pathology. His career goal as a researcher is to develop potential therapeutics for preventing or slowing Parkinson’s disease progression as well as alleviating its symptoms based on understanding the pathology of PD. Since 2002, he has been a member of the Society for Neuroscience (SfN).